Recent Updates
Recently added Catalysts
PCRX Positive Sentiment

Pacira BioSciences to Participate in Fireside Chat at the Barclays 26th Annual Global Healthcare Conference

Key Takeaway: Pacira BioSciences, Inc. (NASDAQ: PCRX) will participate in an analyst-led fireside chat at the Barclays 26th Annual Global Healthcare Conference on March 13, 2024. The event can be accessed live and will also have a replay available for two weeks afterward. Pacira focuses on providing non-opioid treatment options and has three commercial-stage products aimed at pain management, highlighting their commitment to addressing opioid reliance.
Price reaction · baseline $29.44 (2024-03-05 close) · hit after-hours · clean, no other PCRX news in the window
day 0 close · peak
+2.3%

Market Sentiment Analysis

POSITIVE FACTORS

  • Pacira is engaging with analysts, which can improve investor confidence.
  • The mention of non-opioid treatments aligns with growing public health initiatives.
  • The company's initiatives to reduce opioid reliance are timely and relevant.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+19%
120-day peak, hindsight
Typical move
5.7%
average across 5 past catalysts
Lead asset
FX006
Phase 2 · Osteoarthritis of the Shoulder

Full Press Release Details

TAMPA, Fla., March 06, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX) today announced that it will participate in an analyst-led fireside chat at the Barclays 26th Annual Global Healthcare Conference at 1:35 PM ET on Wednesday, March 13, 2024 in Miami. Live audio of the event can be accessed by visiting the “Events” page of the company’s website at investor.pacira.com. A replay of the webcast will also be available for two weeks following the event.
Pacira BioSciences, Inc. (Nasdaq: PCRX) is committed to providing a non-opioid option to as many patients as possible to redefine the role of opioids as rescue therapy only. Pacira has three commercial-stage non-opioid treatments: EXPAREL® (bupivacaine liposome injectable suspension), a long-acting local analgesic currently approved for infiltration, fascial plane block, and as an interscalene brachial plexus nerve block for postsurgical pain management; ZILRETTA® (triamcinolone acetonide extended-release injectable suspension), an extended-release, intra-articular injection indicated for the management of osteoarthritis knee pain; and ioveraº®, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. To learn more about Pacira, including the corporate mission to reduce overreliance on opioids, visit www.pacira.com.

Frequently Asked Questions

When will Pacira participate in the Barclays Healthcare Conference?

Pacira will join the Barclays Healthcare Conference on March 13, 2024, at 1:35 PM ET.

How can I listen to the fireside chat?

You can access the live audio on Pacira's website under the “Events” page.

What is Pacira's mission regarding opioid use?

Pacira aims to provide non-opioid options and reduce reliance on opioids in pain management.

What non-opioid treatments does Pacira offer?

Pacira offers EXPAREL®, ZILRETTA®, and ioveraº® as non-opioid pain management solutions.

Where can I find more information about Pacira?

Visit www.pacira.com for details about Pacira and its treatment options.

Last updated: Mar 6, 2024